{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:57:30Z","timestamp":1790650650002,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Circadian clock dysregulation promotes cancer growth. Here we show that PFKFB3, the gene that encodes for inducible 6-phosphofructo-2-kinase as an essential supporting enzyme of cancer cell survival through stimulating glycolysis, mediates circadian control of carcinogenesis. In patients with tongue cancers, PFKFB3 expression in both cancers and its surrounding tissues was increased significantly compared with that in the control and was accompanied with dys-regulated expression of core circadian genes. In the <jats:italic>in vitro<\/jats:italic> systems, SCC9 tongue cancer cells displayed rhythmic expression of PFKFB3 and CLOCK that was distinct from control KC cells. Furthermore, PFKFB3 expression in SCC9 cells was stimulated by CLOCK through binding and enhancing the transcription activity of PFKFB3 promoter. Inhibition of PFKFB3 at zeitgeber time 7 (ZT7), but not at ZT19 caused significant decreases in lactate production and in cell proliferation. Consistently, PFKFB3 inhibition in mice at circadian time (CT) 7, but not CT19 significantly reduced the growth of implanted neoplasms. Taken together, these findings demonstrate PFKFB3 as a mediator of circadian control of cancer growth, thereby highlighting the importance of time-based PFKFB3 inhibition in cancer treatment.<\/jats:p>","DOI":"10.1038\/srep24324","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T09:10:15Z","timestamp":1460711415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs"],"prefix":"10.1038","volume":"6","author":[{"given":"Lili","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaodong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"key":"BFsrep24324_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0092-8674(02)00722-5","volume":"109","author":"S Panda","year":"2002","unstructured":"Panda, S. et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109, 307\u2013320, (2002).","journal-title":"Cell"},{"key":"BFsrep24324_CR2","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1126\/science.1195027","volume":"330","author":"J Bass","year":"2010","unstructured":"Bass, J. & Takahashi, J. S. Circadian integration of metabolism and energetics. Science 330, 1349\u20131354 (2010).","journal-title":"Science"},{"key":"BFsrep24324_CR3","first-page":"7545","volume":"63","author":"L Canaple","year":"2003","unstructured":"Canaple, L., Kakizawa, T. & Laudet, V. The days and nights of cancer cells. Cancer Res 63, 7545\u20137552 (2003).","journal-title":"Cancer Res"},{"key":"BFsrep24324_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nrc2747","volume":"9","author":"S Sahar","year":"2009","unstructured":"Sahar, S. & Sassone-Corsi, P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer 9, 886\u2013896 (2009).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep24324_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cell.2007.04.015","volume":"129","author":"T Hunt","year":"2007","unstructured":"Hunt, T. & Sassone-Corsi, P. Riding tandem: circadian clocks and the cell cycle. Cell 129, 461\u2013464 (2007).","journal-title":"Cell"},{"key":"BFsrep24324_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature744","volume":"417","author":"K-F Storch","year":"2002","unstructured":"Storch, K.-F. et al. Extensive and divergent circadian gene expression in liver and heart. Nature 417, 78\u201383 (2002).","journal-title":"Nature"},{"key":"BFsrep24324_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nrc1072","volume":"3","author":"L Fu","year":"2003","unstructured":"Fu, L. & Lee, C. C. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3, 350\u2013361 (2003).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep24324_CR8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.4161\/cc.9.6.11046","volume":"9","author":"S Gery","year":"2010","unstructured":"Gery, S. & Koeffler, H. P. Circadian rhythms and cancer. Cell Cycle 9, 1097\u20131103, (2010).","journal-title":"Cell Cycle"},{"key":"BFsrep24324_CR9","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/ijc.27760","volume":"132","author":"M Sot\u00e1k","year":"2013","unstructured":"Sot\u00e1k, M., Polidarov\u00e1, L., Ergang, P., Sumov\u00e1, A. & P\u00e1cha, J. An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors. Int J Cancer 132, 1032\u20131041 (2013).","journal-title":"Int J Cancer"},{"key":"BFsrep24324_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.canlet.2015.12.002","volume":"371","author":"W Jiang","year":"2016","unstructured":"Jiang, W. et al. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer Letters 371, 314\u2013325 (2016).","journal-title":"Cancer Letters"},{"key":"BFsrep24324_CR11","doi-asserted-by":"publisher","first-page":"10618","DOI":"10.1158\/0008-5472.CAN-07-2485","volume":"67","author":"AN Viswanathan","year":"2007","unstructured":"Viswanathan, A. N., Hankinson, S. E. & Schernhammer, E. S. Night shift work and the risk of endometrial cancer. Cancer Res 67, 10618\u201310622 (2007).","journal-title":"Cancer Res"},{"key":"BFsrep24324_CR12","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/jnci\/93.20.1563","volume":"93","author":"ES Schernhammer","year":"2001","unstructured":"Schernhammer, E. S. et al. Rotating night shifts and risk of breast cancer in women participating in the nurses\u2019 health study. J Natl Cancer Inst 93, 1563\u20131568 (2001).","journal-title":"J Natl Cancer Inst"},{"key":"BFsrep24324_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/jnci\/95.11.825","volume":"95","author":"ES Schernhammer","year":"2003","unstructured":"Schernhammer, E. S. et al. Night-shift work and risk of colorectal cancer in the nurses\u2019 health study. J Natl Cancer Inst 95, 825\u2013828 (2003).","journal-title":"J Natl Cancer Inst"},{"key":"BFsrep24324_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.smrv.2012.08.003","volume":"17","author":"EL Haus","year":"2013","unstructured":"Haus, E. L. & Smolensky, M. H. Shift work and cancer risk: Potential mechanistic roles of circadian disruption, light at night and sleep deprivation. Sleep Med Rev 17, 273\u2013284 (2013).","journal-title":"Sleep Med Rev"},{"key":"BFsrep24324_CR15","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1053\/j.gastro.2007.07.009","volume":"133","author":"WA Hoogerwerf","year":"2007","unstructured":"Hoogerwerf, W. A. et al. Clock gene expression in the murine gastrointestinal tract: endogenous rhythmicity and effects of a feeding regimen. Gastroenterology 133, 1250\u20131260, (2007).","journal-title":"Gastroenterology"},{"key":"BFsrep24324_CR16","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1053\/j.gastro.2008.08.048","volume":"135","author":"WA Hoogerwerf","year":"2008","unstructured":"Hoogerwerf, W. A. et al. Transcriptional profiling of mRNA expression in the mouse distal colon. Gastroenterology 135, 2019\u20132029 (2008).","journal-title":"Gastroenterology"},{"key":"BFsrep24324_CR17","first-page":"311","volume":"7","author":"E-Y Oh","year":"2010","unstructured":"Oh, E.-Y. et al. Circadian transcription profile of mouse breast cancer under light-dark and dark-dark conditions. Cancer Genomics - Proteomics 7, 311\u2013322 (2010).","journal-title":"Cancer Genomics - Proteomics"},{"key":"BFsrep24324_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature11048","volume":"485","author":"H Cho","year":"2012","unstructured":"Cho, H. et al. Regulation of circadian behaviour and metabolism by REV-ERB-\u03b1 and REV-ERB-\u03b2. Nature 485, 123\u2013127 (2012).","journal-title":"Nature"},{"key":"BFsrep24324_CR19","first-page":"6267","volume":"47","author":"RR Klevecz","year":"1987","unstructured":"Klevecz, R. R., Shymko, R. M., Blumenfeld, D. & Braly, P. S. Circadian gating of S phase in human ovarian cancer. Cancer Res 47, 6267\u20136271 (1987).","journal-title":"Cancer Res"},{"key":"BFsrep24324_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/(SICI)1097-0215(19970117)70:2<241::AID-IJC16>3.0.CO;2-L","volume":"70","author":"MC Mormont","year":"1997","unstructured":"Mormont, M. C. & L\u00e9vi, F. Circadian-system alterations during cancer processes: A review. Int J Cancer 70, 241\u2013247 (1997).","journal-title":"Int J Cancer"},{"key":"BFsrep24324_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.addr.2007.08.001","volume":"59","author":"B Lemmer","year":"2007","unstructured":"Lemmer, B. Chronobiology, drug-delivery and chronotherapeutics. Adv Drug Deliv Rev 59, 825\u2013827 (2007).","journal-title":"Adv Drug Deliv Rev"},{"key":"BFsrep24324_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","volume":"50","author":"F L\u00e9vi","year":"2010","unstructured":"L\u00e9vi, F., Okyar, A., Dulong, S., Innominato, P. F. & Clairambault, J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50, 377\u2013421 (2010).","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFsrep24324_CR23","doi-asserted-by":"publisher","first-page":"10720","DOI":"10.1158\/0008-5472.CAN-06-2086","volume":"66","author":"I Iurisci","year":"2006","unstructured":"Iurisci, I. et al. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res 66, 10720\u201310728 (2006).","journal-title":"Cancer Res"},{"key":"BFsrep24324_CR24","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/0008-5472.CAN-09-4235","volume":"70","author":"X-M Li","year":"2010","unstructured":"Li, X.-M. et al. Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res 70, 3351\u20133360 (2010).","journal-title":"Cancer Res"},{"key":"BFsrep24324_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0002-9440(10)65306-0","volume":"154","author":"GA Bjarnason","year":"1999","unstructured":"Bjarnason, G. A., Jordan, R. C. K. & Sothern, R. B. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol 154, 613\u2013622, (1999).","journal-title":"Am J Pathol"},{"key":"BFsrep24324_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijrobp.2008.07.009","volume":"73","author":"GA Bjarnason","year":"2009","unstructured":"Bjarnason, G. A. et al. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys 73, 166\u2013172 (2009).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFsrep24324_CR27","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/S0140-6736(85)91551-X","volume":"326","author":"G Rivard","year":"1985","unstructured":"Rivard, G., Hoyoux, C., Infante-Rivard, C. & Champagne, J. Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening. The Lancet 326, 1264\u20131266 (1985).","journal-title":"The Lancet"},{"key":"BFsrep24324_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/00043426-199703000-00002","volume":"19","author":"K Schmiegelow","year":"1997","unstructured":"Schmiegelow, K. et al. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol 19, 102\u2013109 (1997).","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFsrep24324_CR29","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.2337\/diabetes.54.12.3349","volume":"54","author":"T Atsumi","year":"2005","unstructured":"Atsumi, T. et al. Expression of inducible 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase\/PFKFB3 isoforms in adipocytes and their potential role in glycolytic regulation. Diabetes 54, 3349\u20133357 (2005).","journal-title":"Diabetes"},{"key":"BFsrep24324_CR30","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1074\/jbc.M109.058446","volume":"285","author":"Y Huo","year":"2010","unstructured":"Huo, Y. et al. Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response. J. Biol. Chem. 285, 3713\u20133721 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFsrep24324_CR31","first-page":"5881","volume":"62","author":"T Atsumi","year":"2002","unstructured":"Atsumi, T. et al. High expression of inducible 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62, 5881\u20135887 (2002).","journal-title":"Cancer Res"},{"key":"BFsrep24324_CR32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg, O., Wind, F. & Negelein, E. The Metabolism of Tumors in the Body. J Gen Physiol 8, 519\u2013530 (1927).","journal-title":"J Gen Physiol"},{"key":"BFsrep24324_CR33","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/1535-7163.MCT-13-0097","volume":"12","author":"BF Clem","year":"2013","unstructured":"Clem, B. F. et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther 12, 1461\u20131470 (2013).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep24324_CR34","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1074\/jbc.M113.529990","volume":"289","author":"Y Imbert-Fernandez","year":"2014","unstructured":"Imbert-Fernandez, Y. et al. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). J. Biol. Chem. 289, 9440\u20139448 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFsrep24324_CR35","doi-asserted-by":"publisher","first-page":"e24179","DOI":"10.1371\/journal.pone.0024179","volume":"6","author":"M Seo","year":"2011","unstructured":"Seo, M., Kim, J.-D., Neau, D., Sehgal, I. & Lee, Y.-H. Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS ONE 6, e24179 (2011).","journal-title":"PLoS ONE"},{"key":"BFsrep24324_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2049-3002-2-2","volume":"2","author":"AC Klarer","year":"2014","unstructured":"Klarer, A. C. et al. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer Metab 2, 2\u20132 (2014).","journal-title":"Cancer Metab"},{"key":"BFsrep24324_CR37","doi-asserted-by":"publisher","first-page":"16374","DOI":"10.1074\/jbc.M113.539601","volume":"289","author":"H Xu","year":"2014","unstructured":"Xu, H. et al. Myeloid cell-specific disruption of Period1 and Period2 exacerbates diet-induced inflammation and insulin resistance. J. Biol. Chem. 289, 16374\u201316388 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFsrep24324_CR38","doi-asserted-by":"publisher","first-page":"23711","DOI":"10.1074\/jbc.M110.123174","volume":"285","author":"X Guo","year":"2010","unstructured":"Guo, X. et al. Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of PPARg activation in mice. J. Biol. Chem. 285, 23711\u201323720 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFsrep24324_CR39","doi-asserted-by":"publisher","first-page":"e39286","DOI":"10.1371\/journal.pone.0039286","volume":"7","author":"X Guo","year":"2012","unstructured":"Guo, X. et al. Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice. PLoS ONE 7, e39286 (2012).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep24324","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep24324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep24324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T18:30:13Z","timestamp":1672857013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep24324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,26]]}},"alternative-id":["BFsrep24324"],"URL":"https:\/\/doi.org\/10.1038\/srep24324","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]},"assertion":[{"value":"16 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24324"}}